HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010

FRAMINGHAM, Mass. and SYDNEY, Nov. 9, 2010 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that Keith Aaronson, MD, MS, will present data from the ADVANCE Bridge-to-Transplant clinical trial on Sunday, November 14, at the American Heart Association (AHA) Scientific Sessions 2010 at McCormick Place in Chicago.  Dr. Aaronson, Associate Professor in the Division of Cardiovascular Medicine and Medical Director of the Heart Transplant Program and Center for Circulatory Support at the University of Michigan, is a principal investigator of the ADVANCE trial.

The formal presentation, entitled Evaluation of the HeartWare® HVAD Left Ventricular Assist Device System for the Treatment of Advanced Heart Failure: Results of the ADVANCE Bridge-to-Transplant Trial, is scheduled for approximately 4:00 p.m. CST in Hall B.  

Following that presentation, HeartWare will host an investor meeting with CEO Doug Godshall, Dr. Aaronson and Mark Slaughter, MD, to review the trial data at 6:30 p.m. CST (7:30 p.m. EST).  Dr. Slaughter is Professor and Chief in the Division of Thoracic and Cardiovascular Surgery and Director of the Mechanical Assist Device and Heart Transplant Program at the University of Louisville in Louisville, Kentucky, and is also a principal investigator for the ADVANCE trial.

An audio feed of the event will be available to the public via webcast through the Company's website at www.heartware.com by selecting "Bridge-to-Transplant Data Investor Meeting" under the section titled "Corporate Presentations" on the Home Page.  A replay of the webcast will be available through the above weblink shortly following completion of the call.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

SOURCE HeartWare International, Inc.